Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew ...

There will be no hope of restoring political support for pandemic preparedness research, nor public acceptance of it, if virologists seek to continue under a business-as-usual model. Public inclusion ...